Cingulate Inc. Common Stock CING
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:56:39.100Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T21:00:00.179438594Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T13:56:38.773572+00:00
Cingulate Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 3.07 | 193.0% | 35.7% | |||
| 25Δ | 3.23 | 182.4% | 32.7% | |||
| 30Δ | 3.40 | 171.7% | 29.7% | |||
| 35Δ | 3.57 | 161.1% | 26.6% | |||
| 40Δ | 3.74 | 150.4% | 23.6% | |||
| 45Δ | 9.22 | 640.3% | 124.2% | 3.91 | 139.8% | 20.6% |
| 50Δ | 8.41 | 635.5% | 110.6% | 4.08 | 129.1% | 17.6% |
| 55Δ | 7.60 | 630.7% | 96.9% | 4.25 | 118.5% | 14.6% |
| 60Δ | 6.79 | 625.9% | 83.3% | 4.42 | 107.8% | 11.6% |
| 65Δ | 5.99 | 621.1% | 69.6% | 4.59 | 97.2% | 8.6% |
| 70Δ | 5.18 | 616.3% | 56.0% | 4.76 | 86.5% | 5.6% |
| 75Δ | 4.37 | 611.5% | 42.3% | 4.93 | 75.9% | 2.5% |
| 80Δ | 3.56 | 606.7% | 28.7% | 5.76 | 97.8% | 1.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.07
- IV
- 193.0%
- B/E move
- 35.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.23
- IV
- 182.4%
- B/E move
- 32.7%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.40
- IV
- 171.7%
- B/E move
- 29.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.57
- IV
- 161.1%
- B/E move
- 26.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.74
- IV
- 150.4%
- B/E move
- 23.6%
45Δ
- Pseudo strike
- 9.22
- IV
- 640.3%
- B/E move
- 124.2%
- Pseudo strike
- 3.91
- IV
- 139.8%
- B/E move
- 20.6%
50Δ
- Pseudo strike
- 8.41
- IV
- 635.5%
- B/E move
- 110.6%
- Pseudo strike
- 4.08
- IV
- 129.1%
- B/E move
- 17.6%
55Δ
- Pseudo strike
- 7.60
- IV
- 630.7%
- B/E move
- 96.9%
- Pseudo strike
- 4.25
- IV
- 118.5%
- B/E move
- 14.6%
60Δ
- Pseudo strike
- 6.79
- IV
- 625.9%
- B/E move
- 83.3%
- Pseudo strike
- 4.42
- IV
- 107.8%
- B/E move
- 11.6%
65Δ
- Pseudo strike
- 5.99
- IV
- 621.1%
- B/E move
- 69.6%
- Pseudo strike
- 4.59
- IV
- 97.2%
- B/E move
- 8.6%
70Δ
- Pseudo strike
- 5.18
- IV
- 616.3%
- B/E move
- 56.0%
- Pseudo strike
- 4.76
- IV
- 86.5%
- B/E move
- 5.6%
75Δ
- Pseudo strike
- 4.37
- IV
- 611.5%
- B/E move
- 42.3%
- Pseudo strike
- 4.93
- IV
- 75.9%
- B/E move
- 2.5%
80Δ
- Pseudo strike
- 3.56
- IV
- 606.7%
- B/E move
- 28.7%
- Pseudo strike
- 5.76
- IV
- 97.8%
- B/E move
- 1.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 160.23% |
Biotechnology
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
More →CMPX
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple human diseases. The…
More →CNTB
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe…
More →COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. The company is headquartered in Cambridge,…
More →CORT
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company…
More →